Table 3.
Brachial Artery Grayscale Measures by Intervention Group at Baseline and Changes at Week 24
| Total N = 129) |
LDMTX (N = 59) |
Placebo (N = 70) |
Group Difference |
||
|---|---|---|---|---|---|
| Grayscale median | |||||
| Week 0 | N | 124 | 59 | 65 | |
| Median (Q1, Q3) |
74.2 (59.0, 87.7) |
71.8 (55.1, 84.2) |
77.4 (62.1, 91.8) |
||
| Δ to Week 24 | N | 118 | 55 | 63 | |
| Median (Q1, Q3) |
−0.29 (−11.4, 10.5) |
1.54 (−11.1,10.5) |
−1.29 (−12.8, 10.5) |
||
| P-value | 0.54 | 0.93 | 0.42 | 0.55 | |
| Gray level difference statistic-contrast | |||||
| Week 0 | N | 124 | 59 | 65 | |
| Median (Q1, Q3) |
126.1 (84.0, 185.5) |
139.0 (81.8, 195.2) |
120.2 (93.0, 173.4) |
||
| % Δ to Week 24 | N | 118 | 55 | 63 | |
| Median (Q1, Q3) |
7.3% (−21.3, 52.7)% |
25.4% (−18.1, 58.6)% |
1.3% (−29.1, 44.7)% |
||
| P-value | 0.06 | 0.007 | 0.97 | 0.05 | |
| Entropy | |||||
| Week 0 | N | 124 | 59 | 65 | |
| Median (Q1, Q3) |
4.19 (4.03, 4.38) |
4.18 (4.00, 4.39) |
4.20 (4.04, 4.31) |
||
| Δ to Week 24 | N | 118 | 55 | 63 | |
| Median (Q1, Q3) |
0.04 (−0.11, 0.19) |
0.10 (−0.06, 0.23) |
0.02 (−0.11, 0.14) |
||
| P-value | 0.037 | 0.026 | 0.54 | 0.14 | |